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CONTROL AND INDUCTION OF TUMOR NECROSIS FACTOR                       
AND ITS RECEPTORS ON HUMAN LYMPHOCYTES: A CRITICAL 
STRUCTURE FOR IMMUNE REGULATION 
GEORGES TAHHAN 
 
ABSTRACT 
 Type I diabetes (T1D) is an autoimmune disease characterized by the destruction 
of insulin-producing β cells in the pancreas. Destruction of the body’s own proteins, 
cells, and tissues is precipitated by the dysfunction of cytokine production, protein 
modification, and signaling pathways in immune cell subtypes. Tumor Necrosis Factor α 
(TNFα) and its receptors Tumor Necrosis Factor 1 (TNFR1) also known as p55 and 
TNFRSF1A, and Tumor Necrosis Factor 2 (TNFR2) also known as P75 and TNFRSF1B 
play a crucial role in this autoimmune process. TNFα has been shown to stimulate cell 
death through TNFR1 signaling by the caspase system, while promoting cell survival 
through TNFR2 signaling using the Nuclear Factor Kappa-Light-Chain-Enhancer of 
Activated B cells (NF-κB) pathway. Recent findings show a defect in immuno-
proteasomes found in autoreactive T cells in people with T1D. This defect causes 
improper signaling transduction when TNFα binds to TNFR2. The inability to save the 
cell by activating the NF-κB pathway eventually leads instead to apoptosis using the 
caspase system. A decrease in TNFα or increase in soluble TNFα receptors might be an 
explanation for these autoreactive T cells to evade the host immune system, and allow 
them to cause destruction of the pancreas. We hypothesize that patients with T1D will 
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show abnormal distribution of TNFα and its receptors at basal levels, as well as when 
stimulated with interleukins, cytokines, and bacteria such as interleukin-2 (IL-2), 
lipotechoic acid (LTA), granulocyte macrophage–colony stimulating factor (GM-CSF), 
and Bacillus Calmette-Guérin (BCG).  
To test this hypothesis, we obtained peripheral blood from T1D patients (n=102) 
and controls (n=89) and performed in vitro stimulation assays. After a 48-hour 
incubation, tissue culture supernatants were collected and analyzed for TNF and its 
receptors production by ELISA, as well as densities of cell membrane receptors by flow 
cytometry. The data from this study showed significant differences in basal levels of 
TNFα, TNFR1, and TNFR2 on both the membrane and in the serum between patients and 
controls. Patients contained a greater percentage of CD4, 8, and 14 – TNFR2 and not 
TNFR1 double positive cells than their healthy control counterparts. Patient’s sera also 
contained higher levels of all three markers, sTNFα, sTNFR1, and sTNFR2 than the 
controls. However, no significant differences were found between patient and controls 
when stimulated with the various compounds listed above.  
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Chapter 1 - INTRODUCTION 
 
1.1 The Disease 
 Type I diabetes (T1D) is an autoimmune disease, which causes the destruction of 
insulin-producing pancreatic β cells in the Islets of Langerhans. These cells are unable to 
efficiently produce insulin, causing abnormal blood glucose levels, which can lead to 
micro and macro vascular damage if left untreated.  
 Several hypotheses have been proposed throughout the years about what factors 
contribute to the development and progression of T1D. Some of these hypotheses include 
the ‘accelerator’ and ‘overload’ hypothesis where childhood obesity would increase 
insulin demand, overloading β cells and accelerating damage [1]. The ‘Copenhagen 
model’ states that a mixture of the environment, the immune system, and the β cells are 
the main factors that cause type I diabetes. The ‘hygiene’ hypothesis postulates that 
reduced exposure to infectious agents prevents proper immune development and can 
cause a rise of autoimmune disorders [2]. The ‘fertile field’ hypothesis states that 
microbial infections can cause a state of compromised immune system, allowing for 
expansion of auto-reactive lymphocytes [3]. Similar to the fertile field hypothesis is the 
‘old friends’ hypothesis, which focuses on the role of gut flora in type I diabetes. The 
‘threshold’ hypothesis suggests that a mixture of environmental and genetic factors 
causes type I diabetes. Finally, there is the idea that macrophages in the pancreas produce 
higher quantity of cytokines, which causes β cells to be phagocytized by antigen 
presenting cells, which ultimately causes the onset of type I diabetes [4]. 
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 This study places heavy emphasis on the immunobiology aspect of the disease. 
Specifically, how differences in cytokine production such as tumor necrosis factor alpha 
and its receptors might affect viability and action of damaging autoreactive cells.   
 
1.2 Cellular and Molecular Mechanisms of T1D 
Many different kinds of cell subsets contribute to the onset and progression of 
T1D. The main cell types seen thus far to contribute to T1D are macrophages, dendritic 
cells, T cells, and natural killer cells [5]. 
Antigen specific T cells in the pancreatic lymph node can differentiate into either 
pathogenic effector T cells - also called diabetogenic T cells - or into protective T 
regulatory (Treg) cells. Since these cells determine the type of immune response to β cell 
antigens, their balance ultimately determines whether a damaging or a protecting reaction 
occurs in the pancreas. As seen in Figure 1, there are many cell subsets that play a role in 
the immunopathology of type I diabetes. 
Macrophages are recruited to the islet via CD4+ T cell and β cell secretion of CC-
chemokine ligand 1 and 2 [6]. Macrophages are capable of producing interleukin-1β (IL-
1β), interleukin-12 (IL-12), Interferon-γ (IFNγ), Tumor Necrosis Factor (TNFα), and 
Nitric Oxide (NO), which all promote differentiation of diabetogenic CD8+ T cells, and 
can lead to the destruction of β cells. 
Conventional dendritic cells (cDCs) pick up β cell antigens, which then become 
activated. These activated cDCs travel to draining lymph nodes and prime pathogenic 
islet antigen specific T cells and macrophages by release of IL-12, a T-cell stimulating 
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factor. Primed pathogenic islet antigen specific T cells - also called diabetogenic T cells - 
can then proceed in the destruction of β cells in the pancreas. 
However, plasmacytoid dendritic cells (pDCs) and invariant natural killer T 
(iNKT) cells activate Treg cells through the release of indoleamine-2,3-dioxygenase 
(IDO), IL-10, TGFβ and inducible T cell co-stimulator ligand (ICOSL). iNKT, pDC, and 
Treg cells all play an important role in delaying the onset of T1D by inhibiting the actions 
of diabetogenic T cells through secretions of IL-10, TGFβ, and IDO [7]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Cellular Mechanisms for the Development of T1D. After cDC phagocytize β 
cell antigens, it becomes activated and can either stimulate pathogenic islet antigen 
specific T cells which contribute to the development of T1D, or stimulate Treg cells 
which contribute to the protection from T1D (from Lehuen et al.) [7]. 
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1.3 TNFα and its Role in Autoimmunity 
 TNFα is a key protein of the innate immune system. TNFα is secreted by the host 
in response to infection by a microorganism, which leads to the inactivation and 
neutralization of the threat. This innate immune response, of course without the refined 
features of memory, like the T and B cells, has been around for so long as a first line of 
protection. Microorganisms have generically evolved in diffuse ways to thwart the TNFα 
response [8]. Mechanisms to lower biologic TNFα include host shedding of TNFR1 and 
TNFR2 receptors from cell membranes and many more. 
TNFα, aside from being necessary for infection control, also plays an important 
role for several beneficial immune effects. Tregs require the prescience of TNFα to 
survive, but exposure of autoreactive T cells in the periphery to this same TNFα causes 
programed cell death. It has been hypothesized by many that the reason autoimmune 
diseases and allergies are on the rise, is because there has been the elimination of many 
infectious diseases. This hypothesis, as stated earlier, is called the Hygiene Hypothesis. 
We have proposed that TNFα is the central cytokine that is deficient in autoimmune 
prone households of our clean environment, and deficiencies in this cytokine drive the 
rising rates of self-reactive diseases. 
 This hypothesis might seem contradictory since very impressive biologics of anti-
TNFα are mainstream therapy for some forms of autoimmunity like rheumatoid arthritis. 
However, the human data is an important example in that diffuse autoimmune diseases as 
it relates to possible deficiencies of TNFα causes diverse autoimmune diseases such as 
type 1 diabetes, multiple sclerosis, celiac disease, and Crohn’s disease. 
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1.4 TNFα Signaling Pathway Through TNFR1 and TNFR2 
 TNFα is primarily produced and stored on the surface membrane of immune cells 
as a stable homotrimer. From this state, TNFα may become activated by proteolytic 
cleavage by the metalloprotease TNFα converting enzyme (TACE). Once in solution the 
trimeric 51kD TNFα dissociates into singular 17kD TNFα molecules where it reaches full 
activation [9]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Molecular Activation of TNFα by TACE. Association of iRhom2 with 
TACE facilitates its folding and transportation from the endoplasmic reticulum to the 
golgi and subsequently to the surface membrane where it is then able to proteolytically 
cleave TNFα. Once TNFα is cleaved, it dissociates from its trimeric state into singular 
TNFα molecules. At this stage, TNFα can either bind to soluble or membrane bound 
TNFR1 and TNFR2 (from Beutler et al. 2012) [10]. 
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 Once TNFα dissociates from its trimeric form, into its singular form it is 
considered to be biologically active. TNFα is the natural ligand for both TNFR1 and 
TNFR2. At this stage, it can either bind soluble or membrane bound TNFR1 and TNFR2. 
Binding to any of the two soluble TNFα receptors will render TNFα inactive, and will not 
surmount a signaling response. This concept is considered to be a defense mechanism by 
invading hosts such as tuberculosis (TB) to evade detection and destruction by the host 
immune system. The intracellular mycobacterium increases shedding of TNFR2 receptor, 
which then binds and inactivates TNFα thus shielding itself from destruction [11]. 
 TNFR1 is found ubiquitously throughout every cell in the body, while its 
counterpart TNFR2 is more restrictively expressed on certain immune subpopulations. 
Normally, TNFα signaling through TNFR1 pathway will lead to apoptosis through the 
caspase system. On the other hand TNFα signaling through TNFR2 will lead to cell 
survival through activation of NF-κB pathway. However, it has been found that 
autoreactive T Cells have a defective immuno-proteasome which causes the inability to 
activate the NF-κB pathway when stimulated through TNFR2 [12]. This inability of the 
autoreactive T Cell causes the cell instead to signal through the caspase pathway leading 
to apoptosis as seen in Figure 3.  
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Figure 3. TNFα Signaling Pathway Between Normal and Autoreactive T Cells.  TNF 
binding to normal T Cells will elicit either an apoptotic pathway through TNFR1, or cell 
survival pathway through TNFR2. However, defects in the autoimmune cell prevent 
signal transduction through the TNFR2 pathway, thus leading to apoptosis when exposed 
to TNFα. (from Faustman et al. 2010) [12]. 
 
 
 
 Transmembrane TNFα can be found on a wide array of cell populations such as 
macrophages, monocytes, neutrophils, natural killer cells (NK cells), and many 
lymphocytes with exception of CD8+ T cells [13]. The process of secreting this cytokine 
as described above can be in response to many kinds of stimuli such as IFNγ, IL-2, GM-
CSF, and bacterial lipopolysaccharides [14].  
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1.4 Immune Regulation Dysfunction 
Regulatory T cells, also known as Tregs, express forkhead box protein 3 (Foxp3), 
an intracellular transcription factor that is an identifier of this unique cell population with 
surface CD4 expression and high levels of the CD25 (IL2 receptor) [15]. It is well 
appreciated that having sufficient numbers as well as functional Tregs is essential for 
immune tolerance and the prevention of autoimmunity. Indeed early work identified 
people and murine models with FoxP3 gene mutations caused fatal autoimmune diseases 
and allergies [16,17]. The key role of FoxP3 gene in the maintenance of self tolerance 
was first shown in scurfy mice and subsequently in patients with immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (iPeX) syndrome as the causative genetic 
anomaly that results in severe autoimmune diseases and allergy, which resemble the 
diseases observed following depletion of CD4+CD25+ Treg cells in rodents [18-20]. In 
the peripheral blood these cells comprise about 1-4% of the total CD4+ T cell population.  
Identifying Tregs, especially human Tregs has been a multi-year challenge for the 
research community. It would indeed be worthwhile to identify Tregs by more cell 
surface receptors.  TNFR2, unlike its ubiquitous TNFR1 receptor, prominently identifies 
very potent and very functionally suppressive Tregs. Furthermore, the TNFR2 expression 
on Tregs is 10-100x higher than TNFR1 expression [21,22]. 
 
1.5 Identifying And Quantifying Treg Cells In Peripheral Blood 
 Recent technological advances have made it possible to use the methylation status 
of certain genes to distinguish complete cell subtype populations. Activated Treg cells for 
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example contain a specific unmethylated gene named FoxP3. Constant expression of this 
transcription factor is required for the Tregs to maintain their immune regulatory function 
and ensure immune homeostasis [23]. Stable expression of Foxp3 is achieved by 
epigenetic modification of the Treg-specific demethylated region (TSDR). This enhancer 
region is methylated in all other types of cells except for the Tregs. Since only activated 
Tregs have this region unmethylated, it makes it the perfect target for distinguishing 
CD4+ Tregs from other CD4+ cells. 
  
 
 
 
 
 
 
 
Figure 4. Methylation Specific Real Time-PCR. One set of primers can be used to 
amplify a certain area of a gene, which can have one of two hydrolysis probes attached. 
Then ratios of fluorescence between the probe bound to the methylated DNA and the 
probe bound to the unmethylated DNA could be used to quantify the number of Tregs in 
the sample (from Kehrmann et al. 2012) [24]. 
 
 
 
1.6 Effects of Specific Cytokines on the Immune System 
 In this study we focused on the effects of interleukin-2 (IL-2), lipotechoic acid 
(LTA), granulocyte macrophage colony-stimulating factor (GMCSF), and Bacillus 
Calmette–Guérin (BCG) on different immune cell subtypes.  
 IL-2 is secreted by activated CD4+ cells, and has a pleotropic effect on the 
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immune system. It increases Foxp3 transcription in Tregs, increasing their proliferation, 
survival, and suppressive abilities. It also stimulates cytotoxic CD8+ T Cells, as well as T 
helper cells [25]. 
 The study included LTA as a means of simulating the effects of gram-positive 
bacteria. BCG for example is one of the many gram-positive bacteria where LTA serves 
as one of the major cell wall components. Immune cell subtypes such as neutrophil 
granulocytes, and monocytes exposed to LTA soon acquire typical activated cell 
morphology. LTA has been shown to increase secretion of proinflammatory cytokines 
such as interleukin-8, TNFα, and GM-CSF by peripheral blood mononuclear cells 
(PBMC). The proinflammatory cytokines LTA induces are all associated with NF-κB 
pathway, and therefore increased life span of the cells [26]. Granulocyte Macrophage-
Colony Stimulating Factor has been shown to induce the production of TNFα, facilitate 
the maturation of monocytes into macrophages, and increases the viability of monocytes 
during extended periods of in vitro cell culture incubations [27]. 
 Treatment of type 1 diabetic NOD mice with BCG has shown not only to halt the 
progression of the disease, but also provide a permanent cure [28]. In this study the mice 
showed a decrease in autoreactive T cells, an increase in Tregs, and regeneration of the 
pancreas. BCG administered to humans with type I diabetes showed similar but not all 
effects as seen in mice. BCG like LTA stimulated the immune system to induce the 
production of TNFα [29]. 
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1.7 Bacille Calmette Guérin and its Benefits 
 Bacille Calmette Guérin (BCG) is administered in the developing countries as an 
effective vaccination against the mycobacterium tuberculosis. BCG is considered a potent 
immunostimulant. Administration of this mycobacterium normally produces a Th1 
immune response (Figure 5) [31]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Immune Responses to Pathogens. The Th1 response is more effective for 
intracellular pathogens such as viruses and bacteria, whereas the Th2 response is more 
appropriate for extracellular pathogens. (from Cohen et al. 2015) [31].  
 
 
 Production and detection of IFNγ is the key characteristic of a Th1 immune 
response. High IFNγ concentrations activates the bactericidal activities of macrophages, 
the cell mediated innate immunity via activation of NK cells, and increases specific 
cytotoxic immunity using T cell interacting with antigen presenting cells (APC) [32]. 
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Most importantly IFNγ stimulates the secretion of TNFα from mainly activated 
macrophages. 
 The subsequent effects BCG has on the host’s immune system ideally can be 
harnessed and used potentially as a treatment for type I diabetes. BCG activates 
macrophages, which are the main source of TNFα, and also stimulates the release of 
IFNγ, which also stimulates the release of TNFα. TNFα is absolutely required for T reg 
cell viability and function. An increase in Treg cell activity might have suppressive 
effects in several autoimmune disease such as type I diabetes [33]. 
 
1.8 Purpose and Hypothesis 
 The purpose of this study is to compare tumor necrosis factor receptor densities 
on the membrane, and the rate of shedding of these receptors from specific immune cell 
subtypes between controls and people with type I diabetes for both basal and stimulated 
conditions. This study is also interested in observing the functional effects of BCG in 
respect to TNF, its receptors, and viability of certain immune cell subtypes.  
 We hypothesize the TID subjects would exhibit increased TNFR1 and TNFR2 
both basally and following stimulation compared to healthy controls. We also 
hypothesize that the presence of BCG would increase the number of active Tregs cells. 
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Chapter 2 - METHODS  
 
2.1 Ethics Statement and Study Population 
 Peripheral blood was obtained by venipuncture from patients with type 1 diabetes 
and healthy controls with full institutional approval from Massachusetts General 
Hospital. Written informed consent was obtained from all patients or from patient 
guardians, as appropriate (MGH/Partners Protocol #2001P001379). Four BD vacutainer 
EDTA 10 mL vials, and 1 BD vacutainer serum 10mL vial (BD, Franklin Lakes, NJ) 
were collected from each participant. All blood used in these experiments was fresh, and 
processed within two hours from blood draw. 
A total of 191 randomly chosen participants were enrolled in the study. The 
clinical characteristics of both the type I diabetics and controls used in this study are 
presented in Table 1. 
 
Table 1. Study Subject Characteristics. Three distinct populations were studied. Their 
age, duration of disease, and age of onset (if applicable) are listed as means with standard 
errors. 
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People with type I diabetes were of ages ranging from 11 to 72 years, and had 
disease durations of at least 2 years.  All control subjects neither had an autoimmune 
disease nor a family history of autoimmune diseases.  The non-autoimmune disease 
controls were all between 14 and 69 years of age. The diagnosis of type I diabetes was 
based on the criteria of the American Association of Clinical Endocrinologists (AACE) 
and American College of Endocrinologists (ACE).  
 
2.2 Isolation of PBMC’s From Blood 
 The BD Vacutainers containing EDTA were used for isolation of peripheral blood 
mononuclear cells. All PBMC’s were isolated using ficoll-hypaque PLUS gradient (GE 
Life Sciences). Blood was carefully layered over the ficoll in a 50 mL falcon tube, for a 
final one-to-one ratio of blood to ficoll. The tube was centrifuged at 400 x g for 20 
minutes at 4°C. The lymphocyte layer was transferred to a clean 50mL falcon tube, and 
was filled to the brim with Hanks Balanced Salt Solution (HBSS) to wash away any 
unnecessary platelets and plasma proteins. The tube was centrifuged at 400 x g for 10 
minutes at 4°C. The pellet of cells were resuspended with 4 mL lysis buffer, and placed 
on ice for 7 minutes. Following lysis, the contents were transferred to a clean 15mL 
falcon tube, and washed with HBSS to remove any residual lysis buffer. The tube was 
then centrifuged at 400 x g for 10 minutes at 4°C. The pellet of cells was then 
resuspended with tissue culture media consisting of 1640 RPMI with 20% fetal bovine 
serum and 1% L-Glutamine and 1% Penicillin/Streptomycin. At this time, a 100µL cell 
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sample was mixed with 100µL Trypan Blue and counted using a hemocytometer. The 
tube was centrifuged 400 x g for 10 minutes at 4°C and resuspended in tissue culture 
media to provide a concentration of 5 x 106 cells/500µL. 
 
2.3 Stimulated Tissue Culture Assay  
 After isolating the PBMC, and resuspending the cells to make a concentration of 5 
x 106 cells/500µL, 500µL was pipetted into each well in a 24-well tissue culture plate. 
The samples were divided into 5 batches.  The first batch of 500µL containing 5 x 106 
cells received an additional 500µL of tissue culture media, and was not stimulated. This 
batch served as a comparison to the rest of the stimulated batches. The rest of the batches 
received, 10,000units Interleukin-2 (IL-2) (Life Technologies), 10mcg Lipotechoic Acid 
(LTA) (Sigma Aldrich), 10 mcg LTA + 100ng Granulocyte Macrophage Colony-
Stimulating Factor (GMCSF), and 1.56 x 105 Bacillus Calmette–Guérin (BCG) (Sanofi), 
respectively. Each stimulated sample contained 5 x 106 cells, the specific treatment, and a 
supplement of tissue culture media for a total volume of 1mL. The 24-well tissue culture 
plates were incubated for 48 hours at 37°C 5% CO2 with a cover but no slip. 
 Following 48 hours incubation, samples were harvested. The contents of each 
well were transferred to their respective clean 1.5mL eppendorf tubes. The tubes were 
centrifuged for 6 minutes at 4500 rpm in 4°C. The supernatant was collected and stored 
in -80°C for future ELISA’s, and the cells were resuspended with 1mL of tissue culture 
media for analysis using flow cytometry. 
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2.4 Flow Cytometry 
Following 48 hours incubation, 100µl of cells were collected from each well of 
the 24-well plate and transferred into a 1.5ml eppendorf tube. For cell surface 
immunostaining, we used fluorescein isothiocyanate (FITC)-, allophycocyanin (APC)-, 
and phycoerythrin (PE)-conjugated monoclonal antibodies against CD4 (clone RPA-
T4)/CD8 (clone HIT8a), TNFR1 (clone 16803)/TNFR2 (clone 22235), and CD14 (clone 
M5E2) respectively. CD4, CD8, and CD14 antibodies were all from BD Bioscience 
Pharmingen, Franklin Lakes, NJ. TmTNFα, TNFR1, and TNFR2 antibodies were all 
from R&D Systems, Minneapolis, MN. All antibodies were from mouse with human 
reactivity.  
10µL of antibody was pipetted into the 100 µL sample of cells, and placed in the 
dark for incubation in 4°C for 20 minutes. Following incubation, cells were washed with 
1mL of tissue culture media, and centrifuged for 6 minutes at 4500 rpm in 4°C. The 
supernatant was discarded, and cells were resuspended in 300µL. The sample was then 
transferred to a clean polystyrene flow cytometry tube, and was measured using BD 
FACSCalibur and the CellQuest acquisition program. The cell count was set to a total of 
11,000 events counted and the same channels were used.   
 
2.5 Isolation of Human Serum 
 The blood collected in the BD vacutainer serum was used for serum isolation. The 
tube was centrifuged at 400 x g for 15 minutes at 20°C. This separated the blood into two 
components. The top component containing the serum was transferred into four sterile 
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2mL cryovials, and stored in -80°C for use in future experimentation and analysis. 
 
2.6 Enzyme-Linked Immuno-Sorbent Assay (ELISA) 
 TNFα, sTNFR1, and sTNFR2 were detected by standard sandwich ELISA with a 
HRP/TMB readout (R&D Systems, Minneapolis, MN). The tissue culture supernatants 
were diluted 50-fold for sTNFR2 detection, and 2.5-fold for sTNFR1 detection. The 
human serum was diluted 20-fold for both sTNFR2 and sTNFR1 detection. No dilutions 
were necessary for TNFα detection in either tissue culture supernatants, or human serum. 
Manufacturers instructions were followed. The optical density was then determined at 
450 nm by a spectrometer (Spectramax 190) and values compared to a standard curve to 
determine unknown concentration. 
 
2.7 Isolation of CD4+ T Cells from Blood 
 All CD4+ cells were isolated using Dynal magnetic beads methods (Product Nos 
113–33D, Invitrogen).  Blood and beads were both washed and suspended in Hanks 
Balanced Salt Solution (HBSS) supplemented with 2% fetal bovine serum. 16µl of fresh 
blood was added to a 50ml conical tube. The blood in the conical flasks was washed 
twice. 600µl of beads were used for 48µl of fresh blood (100µl beads per 8µl blood).  
200µl beads were added to each 15ml conical tube. The beads in the conical tubes were 
washed twice with 8ml of washing buffer. During the wash the 15ml conical tubes were 
placed in a magnet for 1 min and then the supernatant was aspirated. After washing the 
beads, they were resuspended in 600µl washing buffer per 15ml conical flask. After 
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being washed, the blood from each 50ml conical flask was added to one set of the 600µl 
resuspended beads and incubated at 4⁰C for 20 min with gentle tilting rotation. The 15ml 
conical tubes containing the blood and beads were then placed in a magnet for 2 min and 
the supernatant was discarded. The tubes were removed, 8ml of washing buffer was 
added to each 15ml conical tube and then pipetted up and down vigorously. The 
suspensions were then added to fresh 15ml conical tubes. This process was repeated 3 
times to obtain a high purity of CD4+ cells (97% or more purity). The cell pellets in each 
15 ml conical tube were then resuspended in 1ml washing buffer.  80µl of 
DETACHaBEAD was added to each cell pellet. The cell pellets and DETACHaBEAD 
were incubated for 1 hour at room temperature with gentle mixing. The tubes were placed 
in the magnet for 1 minute and the supernatant was transferred to a fresh 15ml conical 
tube. This step was repeated twice. The cell suspensions from the different 15ml conical 
tubes were combined in one 15ml conical tube. 10µl of the cell suspension was pipetted 
onto a hemocytometer and counted. 
 
2.8 DNA Extraction from CD4+ T Cells  
 5 x 106 CD4+ Cells were resuspended in 200µl PBS. The isolation of DNA from 
these cells was performed with the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s protocol. DNA purity was measured using the 
Spectramax 190.  
 
	  19 
3.0 Real Time-PCR Quantification of Tregs 
 Real Time-PCR was performed in white 96-well optical trays with the Roche 
LightCycler 480 system (Roche Diagnostics, Basel, Switzerland) to a final reaction 
volume of 20µL, containing 10µL 2-fold Roche TaqMan Probe Master 480, 2µL 
bisulfite-treated DNA, 1µM of each primer (FOXP3qPCRfw, GAAATTTGTGGGGTGG 
GGTATTTGTTTT; FOXP3qPCRrev, ATCTACATCTAAACCCT ATTATCACAACCCCC). 
The probes (VIC-labeled methylated FOXP3, TCGGCGTATTC GG; FAM-labeled 
unmethylated FOXP3, AGTTTGGTGTATTTGGT) were added to a final concentration of 
166nM. All samples were analyzed in duplicate. After initial denaturation at 95°C for 10 
min, the samples were subjected to 40 cycles at 95°C for 15 sec and at 60°C for 1 min 
[24]. 
 
3.1 Statistical Analyses 
After data acquisition, the data (flow .fcs files) was imported into Flowjo 
Software (ver 10.0.7r2 for Mac OS X) for analysis (Flowjo, LLC, 385 Williamson Way, 
Ashland, CA 97520). A polygate was used to include the lymphocyte cluster, and another 
more general polygate was used to include all PBMC’s. These polygates were placed in 
the forward and side scatter dot plots. All samples were double labeled with TmTNFα, 
TNFR1, or TNFR2 and their respective CD marker.  
A series of quadrant gates were used to divide the selected cell population using a 
two-dimensional dot plot with the x-axis being the CD marker and the y-axis being either 
TNFR1 or TNFR2. The upper right quadrant provided the percentage of cells, which 
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were positive for both antibodies. The median fluorescence intensity (MFI) was obtained 
by gating on the CD positive cells. The Flowjo software was then used to determine the 
MFI of the cells gated.  
The calculated MFI, and upper right percent positive cells values were imported 
(or manually entered) into Prism Software  (Prism 6 (Ver 6.0c) for Max OS X, GraphPad 
Software, Inc., 7825 Fay Avenue, Suite 230, La Jolla, CA 92037).   
The Student’s T test was used to compare differences in means of two groups. In 
this study it was used to compare variances of percent of cells which were positive for 
TNF receptor and their CD marker between patients with type I diabetes and controls, as 
seen in Figure 5. It was also used to compare variances of cytokine production between 
patients with type I diabetes and controls as seen in Figure 6. The T test was performed as 
a two-tailed calculation with a 95% confidence interval. 
The Spearman correlation was used to analyze and compare age and disease 
duration to TNFα, sTNFR1, and sTNFR2 production between patients with type I 
diabetes and control, as seen in Figures 9-11. The Pearson correlation coefficient 
calculation was also used to determine the significance of spread, as seen in Figures 9-11. 
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Chapter 3 - RESULTS 
 
3.1 Basal TNFR1 and TNFR2 Expression on Immune Cell Subtype Membranes 
 The results comparing the expression of TNFR1 and TNFR2 densities on surface 
membranes of immune cell subtypes between T1D and controls did support our 
hypothesis. The data shows significant differences between T1D and controls with 
respect to percent TNFR2 positive CD4, 8, and 14 cells. There was no difference in 
means or variance of percentage of TNFR1 positive cells between T1D and controls 
under the conditions tested.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6. TNFR1 and TNFR2 Surface Expression Profiles. From these dot plots the 
differences between patients and controls with respect to surface membrane TNFR1 and 
TNFR2 can be easily discerned. Patients have significantly higher percentages of CD4, 8, 
and 14 cells with TNFR2. The distribution of TNFR1 across the cell subtypes between 
patients and controls are the same.  
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Figure 7. Comparison of TNFR1 Expression Between Patients and Controls. There 
is no significant difference of expression of TNFR1 on the surface membrane of immune 
cell subtypes between patients and controls.  
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Figure 8. Comparison of TNFR2 Expression Between Patients and Controls. Patients 
and controls show significant differences in the percentage of CD4, CD8, and CD14 that 
are TNFR2 positive. 
 
3.2 Basal Levels of TNFα, sTNFR1, and sTNFR2 in Serum 
 The results from comparing serum concentrations of soluble TNFα, sTNFR1, and 
sTNFR2 between patients with T1D and controls did support our hypothesis (Figure 9). 
The data shows significant differences between T1D and controls with respect to all 
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cytokines and receptors studied. Patients showing complications such as renal failure, 
retinopathy, and hypertension were placed in a separate group. The patients with 
complications also showed significant differences in serum concentrations of TNFα, 
sTNFR1, and sTNFR2 when compared to patients without complications as well as 
controls. Please refer to Table 2 for a summary of the means and standard errors, and 
Table 3 for a summary of the P Values for Figure 8. 
 
 
 
 
 
 
 
 
 
 
Figure 9. Basal Serum Levels of TNFα, sTNFR1, sTNFR2. There are significant 
differences across all subjects and molecules studied. Refer to Table 2 for exact P-values. 
 
 
 
Table 2. Summary of the Data Plotted in Figure 8. Listed in this table are the means 
plus or minus the standard error for the molecules being studied for all study subjects. 
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Table 3. Summary of P Values Comparing Figure 8 Populations. There are 
significant differences of basal serum concentration of TNFα, sTNFR1, sTNFR2 between 
controls, patients, and patients showing complications. 
 
 
 
 
 
 
 
3.3 Effects of Disease Duration on TNFα, sTNFR1, and sTNFR2 Levels in Serum 
 Interestingly disease duration shows significant effects with respect to the three 
molecules being studied. As the duration of T1D increases, patients were shown to have 
decrease serum TNFα, and increased sTNFR1, and sTNFR2. This effect was only seen 
when comparing duration of disease; age has no influence in affecting serum 
concentrations of TNFα, sTNFR1, and sTNFR2 (Figures 10-12 and Tables 4-6).  
  
 
 
 
 
 
 
 
 
 
 
Figure 10. Effects of Disease Duration on TNFα, sTNFR1, and sTNFR2 Serum 
Levels. TNF decreases as the duration of T1D increases. Whereas, sTNFR1 and sTNFR2 
increase as the duration of T1D increases.  
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Table 4. Effects of Disease Duration on TNFα, sTNFR1, and sTNFR2 Serum Levels. 
All three graphs show strong correlations, and all have significant slopes compared to the 
horizontal 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Effects of Age on TNFα, sTNFR1, sTNFR2 Serum Levels in Patients. 
These three graphs show how patient’s age might affect serum TNFα, sTNFR1, and 
sTNFR2 concentrations. 
 
 
Table 5. Effects of Age on TNFα, sTNFR1, and sTNFR2 Serum Levels in Patients. 
Both sTNFR1 and sTNFR2 concentrations are not affect by age. However, an increase in 
a patient’s age correlates with lower TNFα. 
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Figure 12. Effects of Age on TNFα, sTNFR1, sTNFR2 Serum Levels in Controls. 
These three graphs show how control’s age might affect serum TNFα, sTNFR1, and 
sTNFR2 concentrations. 
 
 
 
Table 6. Effects of Age on TNFα, sTNFR1, sTNFR2 Serum Levels in Controls. Age 
has no significant effect on serum TNFα, sTNFR1, and sTNFR2 concentrations 
 
 
 
 
 
 
 
 
 
3.4 TNFR2 Expression on Monocyte Cell Membranes Following Stimulation 
 The results from comparing the expression of TNFR2 densities on surface 
membranes of monocytes between T1D and controls following 48 hours stimulation with 
various compounds did not support our hypothesis. The data shows no significant 
differences between T1D and controls with respect to TNFR2 MFI or percent CD14-
TNFR2 double positive cells. However, Figure 13 does show the effects of the 
compounds on monocytes. The stimulated samples were normalized with respect to the 
non-treated samples. There are less double positive (TNFR2, CD14) cells following IL-2 
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stimulation. Both patient and control samples increase in the amount of cells containing 
both markers (TNFR2, CD14) when stimulated with LTA, and LTA-GMCSF. TNFR2 
MFI showed no significant change in any of the conditions tested (Figure 13).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Changes in CD14-TNFR2 Positive Cells and TNFR2 MFI. Ratios of 
treated to untreated samples were calculated and graphed. No treatment was normalized 
to 1 and all other samples are expressed as fold differences in comparison to no 
treatment. 
 
 
3.5 TNFα, sTNFR1, and sTNFR2 Concentrations Following Stimulation 
The results from comparing tissue culture supernatant concentrations of sTNFα, sTNFR1, 
and sTNFR2 between patients with T1D and controls did not support our hypothesis. The 
data shows no significant differences between T1D and controls with respect to all 
cytokines and receptors studied. All three markers increased significantly following 
48hours stimulation (Figure 14). 
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Figure 14. In Vitro Induction of TNFα, sTNFR1, and sTNFR2. Comparison of 
concentrations of TNFα, sTNFR1, and sTNFR2 following 48 hours of stimulation. Tissue 
culture supernatants were collected and analyzed for these markers.  	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3.6 Effects of BCG Treatment on Monocytes 
  The results from these experiments did not support the hypothesis. Both the 
patients and controls responded equally to the 48hour BCG treatment. Even though no 
differences were noted between patients and controls, these experiments did shed light on 
the effects of BCG on cell surface markers, and proliferation of CD14 cells.  
 BCG significantly increases the percentage of CD14-TNFR2 double positive 
cells, with the receptor density staying the same regardless of stimulation (Figure 15).  
 Its effect on TNFR1 density on CD14 surface membranes is extremely drastic. 
Stimulation with BCG causes a significant decrease in trans-membrane TNFR1. Due to 
this decrease in density of receptors on the cell membrane, the data also shows a slight 
but not significant decrease in the percentage of TNFR1-CD14 double positive cells 
(Figure 16).  
 There is a slight induction of CD14-TNFα double positive cells, but not 
significant. The density of trans membrane TNFα is not affected by stimulation with 
BCG (Figure 17).  
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Figure 15. Effects of BCG on TNFR2 Expression on Monocytes. BCG induces 
proliferation of CD14-TNFR2 double positive cells, while keeping the density of the 
TNFR2 receptor constant.  
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Figure 16. Effects of BCG on TNFR1 Expression in Monocytes. BCG significantly 
decreases the receptor density of TNFR1 on CD14 cells following 48hours incubation. It 
also causes a slight decrease in the percentage of CD14-TNFR1 double positive cells.  
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Figure 17. Effects of BCG on Trans Membrane TNF-α Expression on Monocytes. 
BCG does not significantly change either the percentage of CD14-TmTNFα double 
positive cells, nor the TmTNFα density on those cells. 
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3.7 Tissue Culture Supernatant Following BCG Treatment 
 There were no significant differences in cytokine production following 48hours 
stimulation with BCG between patients and controls. Both patient and controls secreted 
equal amounts of the three markers in response to BCG treatment (Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. sTNFα, sTNFR1, and sTNFR2 Concentrations Following BCG 
Treatment. These dot plots show a significant induction of all three markers following 
48hours incubation with BCG.    
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Chapter 4 - DISCUSSION 
  
As the results show, T1D subjects do show elevated levels of the cytokine TNFα 
and its receptors in comparison to their healthy control counterparts under certain 
conditions. Stimulation of PBMCs with TLR-7 agonist IL-2, bacterial TLR-2 agonist 
LTA, a combination of LTA and GMCSF, and with mycobacterium BCG showed no 
significant variation between patients with T1D and controls. However, basal serum 
concentrations and baseline expression of TNF receptors on certain immune cell subtype 
populations do show differences between people with T1D and controls. Grouping the 
data by disease duration revealed long-term influences of disease with levels of 
cytokines. The data shows a longer disease duration is associated with decreased levels of 
TNFα and an increase in both sTNFR1 and sTNFR2. This supports the hypothesis that 
TNFα plays a central role in autoimmune disease progression.  
 Many autoimmune diseases are associated with low TNF levels, and disease 
progression is clearly demonstrated with anti TNF therapies (Table 7). There is 
supporting evidence from other studies that anti TNF therapies can be beneficial under 
certain conditions, treating rather than exacerbating specific types of autoimmune 
diseases. A perfect example is multiple sclerosis (MS), where patients given anti TNF 
therapies showed worsening symptoms and progression of the disease. Two patients with 
MS were enrolled in an early phase I safety trial, one received an anti TNF therapy while 
the other patient received the placebo. The results from this study showed an increase in 
demyelinating lesions in the central nervous system (CNS) and decrease immune system 
activity in the cerebrospinal fluid (CSF) [34]. Another example of this same effect of anti 
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TNF therapies for patients with MS can be seen in a double blind phase II safety trial. 
The trial showed that 168 patients with MS received no benefit from the anti-TNF 
therapy, and also showed worsening of the disease. The rate of worsening was 50% grater 
in the treated group than from the placebo group [35]. Development of MS and other new 
onset demyelinating disease has been found in cases where the anti TNF drug Infliximab 
was being used to treat Colitis and Crohn’s disease [36,37].  
 Infliximab therapy in 125 Crohn’s patients results, after 24 months, in a high 
cumulative incidence (57%) of patients developing antinuclear antibodies, two patients 
developing drug-induced lupus and one patient developing autoimmune hemolytic 
anemia [38]. In rheumatoid arthritis, therapy with TNF antagonists in all therapeutic 
forms is associated with relatively common and detectable autoimmune adverse events, 
including demyelinating disease, confirmed forms of MS, autoimmune hemolytic anemia, 
type 1 diabetes, a lupus-like syndrome, and cutaneous lupus rashes. Further, 11%–57% of 
patients develop new or elevated antinuclear antibodies, usually within 1 year of therapy 
initiation [38–46]. Approximately 7%–15% of patients develop new antibodies against 
double-stranded DNA [42, 44]. 
 Recently, a case of type I diabetes was reported in a 7-year old girl undergoing 
treatment for juvenile rheumatoid arthritis with a TNF antagonist [47]. The induction of 
new onset autoimmunity or the occasional worsening of autoimmunity is an apparent 
class effect of anti-TNF therapy and is not unique to any given TNF antagonist.  
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Table 7. Levels of TNFα, TNFR1, and TNFR2 in Various Diseases. A review of the 
current literature on various autoimmune and non-autoimmune diseases and the role 
TNFα and its receptors play in disease onset, progression, or treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Future directions for this study might include, determining effects of BCG on 
specific isolated immune cell subtypes. The bacterial antigen LTA and GMCSF may be 
switched for different ligands or even antibodies which elicit a stronger response. It 
would be interesting to observe weather the BCG bacteria can be detected in humans 
after years of inoculation. Since the goal is to elicit long-term responses from few doses 
of BCG, then viral vectors might be an option. The use of a bacteriophage would allow 
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the incorporation of bacterial DNA into the host. With the DNA incorporated into the 
host, the bacteria’s effect will last a lifetime. The study of BCG’s effects on specific 
immune cell subtypes also requires the study of their cytokine secretion profiles. It would 
be interesting to note whether the administration of BCG changes the cytokine secretion 
profile of certain immune cell subpopulations. 
Current literature lacks information regarding BCG’s functional effects, and 
subsequent contribution it might have towards the protection and possibly cure of T1D. 
This study represents a step toward defining the use of BCG as a means to an end in type 
1 diabetes and possibly other autoimmune diseases, providing further insight into their 
mechanism of pathogenesis and opportunities for treatment.   
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the pharmacy served: CICU, SICU, Surgery, NICU, Pediatrics, Med/Surge, BurnICU, 
NeuroICU, OBGYN, Trauma, PICU. This job also allowed me to network throughout 
these services and explore possible career options. 
 
Honors & Awards 
 
Post Bacc Intramural Research Training Award NIH: October/2012 
 This award provided the opportunity to spend my gap year prior to applying to 
medical school performing full-time research in Dr. Notkins lab in the National Institute 
of Dental and Craniofacial Research Experimental Medicine Branch. 
 
Summa Cum Laude from the University of Florida: August/2012 
 After writing my senior thesis based off of the type 1 diabetes research conducted 
in Dr. Mark Atkinson’s Lab, the University of Florida granted me the honor of graduating 
with highest honors from their College of Liberal Arts and Science. 
 
Dean’s List Spring 2012: April/2012 
 During the spring semester of 2012 I took 18 credits and had a 3.88 GPA. For this 
reason I was placed on the Dean’s List. 
 
Florida Medallion Scholars Award: September/2008 
 Due to my high school grades, I was awarded this merit-based scholarship, which 
allowed me to finish my undergraduate career without debt. 
 
Miami Beach Kiwanis Scholars Award: September/2008 
 My involvement in the Miami Beach Kiwanis Club allowed me to apply for this 
scholarship and my above average grades in high school was the factor that granted me 
this merit-based scholarship of $1000. 
 
Summa Cum Laude from Miami Beach Senior High School: June/2008 
 I graduated in the top 5% of my high school, which allowed me to graduate with 
highest honors from the Miami Beach Senior High School. 
 
Extracurricular & Avocation Activities  
 
Active Member of the Society for Advancing Hispanics/Chicanos & Native American in 
Science (SACNAS)  
Former Member of the Racquetball team at the University of Florida 
Licensed in-patient pharmacy technician by the state of Florida 
	  52 
Licensed open water scuba diver by National Association of Underwater Instructors 
(NAUI) 
 
Language Proficiency 
 
English – Native: Speaking/Reading/Writing 
Spanish – Native: Speaking/Reading/Writing 
Arabic – Basic: Speaking/Reading/Writing 
 
